Completed PHASE4 INTERVENTIONAL 1-arm NCT00198263

Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer

An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer

Sponsor: Inovio Pharmaceuticals

Interventions Medpulser Electroporation with Bleomycin

Updated 6 times since 2017 Last updated: Sep 27, 2017 Started: Jan 31, 2004 Primary completion: Sep 30, 2008 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00198263, this PHASE4 trial focuses on Head and Neck Cancer and remains completed. Sponsored by Inovio Pharmaceuticals, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Apr 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inovio Pharmaceuticals

Data source: Inovio Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Diego, United States